Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood markers could spot sepsis risk early

NCT ID NCT02545478

First seen Apr 16, 2026 · Last updated Jun 23, 2026 · Updated 11 times

Summary

This study is looking at whether early signs of inflammation in the blood can help identify which patients with infections are at risk for serious complications like sepsis. Researchers will follow 4,200 adults with confirmed or suspected infections, as well as healthy controls, to see how well these biomarkers predict death or organ failure within 28 days. The goal is to improve early detection and treatment of severe infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    ACTIVE_NOT_RECRUITING

    Boston, Massachusetts, 02114, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to better tools for early detection of severe infections, helping doctors intervene sooner and potentially reduce deaths from sepsis.

What could go wrong

This is an observational study, not a treatment trial. It may not directly improve patient outcomes, and the biomarkers might not be accurate enough for widespread use.

Conditions

The condition(s) this trial relates to.

Infections infectious disease with sepsis Inflammation inflammatory disease Pathologic Processes Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.